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minutes for another hour. A CBC (complete blood count) is drawn
when the patient returns to the unit and then repeated in four
hours. If the patient is hemodynamically unstable or the post-
procedure CBC shows 1g/dl change from baseline hemoglobin,
the CBC is repeated every hour for four hours.
Order sets outlining pre and post-procedure orders have been
developed and are available through the electronic order pathway.
There is also a plan in place to audit compliance with the Plan of
Care and the appropriate use of liver biopsies.
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SIBLING SUPPORT PROGRAM: MODEL FOR MULTIDISCIPLINARY IN-
TERVENTION INITIATED BY NURSING
Skeens, M.A.1, Canner, J.1, Garee, A.M.1, Young-Saleme, T.1,
Termuhlen, A.1 1Columbus Childrens Hospital, Columbus, OH.
According to research, healthy siblings are identiﬁed as the most
disregarded and distressed of all family members affected by seri-
ous childhood illness. In an effort to increase communication and
coping in these families, a multidisciplinary team at Columbus
Children’s Hospital implemented a sibling support program. The
pilot group targeted siblings of children with cancer age 8-12. The
program consisted of six modules related to facts about cancer,
feelings, change, and support. The siblings were also exposed to
areas of the hospital they may never see, including MRI, CT,
XRAY, and the operating room. A coinciding parent group was
conducted with a trained psychologist. A total of ﬁfteen children
and ﬁfteen parents participated. Both parents and siblings were
surveyed using a questionnaire developed by the multidisciplinary
team. Eleven children and eight parents completed the survey.
72% of children reported that the group enabled them to talk more
openly to their parents about their feelings. 82% stated that the
group taught them more effective ways to cope with their ill
sibling. The parent data indicated that 86% believed the group
helped foster communication with their well child. All of the
parents stated that the group helped their child cope more effec-
tively with the illness of their sibling. This preliminary data sug-
gests that a formal support program increases coping skills of the
sibling, as well as fosters communication between parents and their
well child. Future research, including a prospective study using the
Sibling Perception Questionnaire, as well as development of an
adolescent support group is planned.
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GATIFLOXACIN AS A POSSIBLE CAUSE OF HYPOGLYCEMIA IN A NON-
DIABETIC STEM CELL TRANSPLANT PATIENT
Smith, V.P.1, Gulbis, A.M.1, Sorensen, S.1 1University of Texas MD
Anderson Cancer Center, Houston, TX.
Introduction: Gatiﬂoxacin, a broad-spectrum ﬂouroquinolone
with relatively benign adverse effect proﬁle, and once-daily dosing,
provides an easy and convenient regimen for patients treated both
in and outside the hospital. Since the Food and Drug Administra-
tion approved the antibiotic in 1999, the prescribing information
has been updated to include stronger precautions of possible dis-
turbances of glucose homeostasis. With increased use of gatiﬂoxa-
cin comes reports of increased incidences of interruption of glu-
cose homeostasis. Although gatiﬂoxacin has been previously
reported as a potential cause of both hypoglycemia and hypogly-
cemia, the exact mechanism is unknown.
Purpose: The process of diagnosis, collaboration with multisci-
plinary teams, and management of the patient as well the informa-
tion learned from this experience with be shared with fellow col-
leagues.
Summary: A 61 year-old female with a history of lymphoma s/p
allogenic stem cell transplant in 1999. She remains in remission
from that disease but has been having chronic graft versus host
disease of the eyes for which she has received chronic steroids as
well as continuing photopheresis. More recently she is being
treated for fungal pneumonia and chronic renal failure. The pa-
tient has been taking gatiﬂoxacin for several years. However, a few
weeks prior to developing symptomatic hypoglycemia, she had an
acute worsening of her chronic renal failure. The patient presented
to the clinic complaining of feeling weak, shaky, and dizzy and not
feeling well, her fasting blood glucose was 37 at that time. She was
given dextrose 50% and admitted for uncontrolled hypoglycemia
and worsening fungal pneumonia. The patient was evaluated by
endocrinology and her gatiﬂoxacin was discontinued with normal-
ization of her glucose without further interventions.
Implications for Nurse Practitioners: The temporal relation-
ship of the gatiﬂoxacin administration and the decreased glucose
levels seems to correlate in our patient. The patient’s renal insuf-
ﬁciency may have also contributed to the hypoglycemia. Gatiﬂoxa-
cin does exihibit an insulin-secreting property that is not fully
understood, but is clinically signiﬁcant. Therefore, clinicians
should be aware of that possible adverse effect and act quickly if
their patient develops hypoglycemia when taking gatiﬂoxacin.
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FLEX TIME: AN OPPORTUNITY FOR EMPLOYEE SATISFACTION IN THE
TRANSPLANT COORDINATOR TEAM
Stary, S.J.1, Koval, E.1 1UT MD Anderson Cancer Center, Houston,
TX.
The implementation of Flex Time was made in an effort to
recognize overall employee satisfaction, maintain a seamless expe-
rience of nursing care for the patient, and maintain professional
service to all collaborating teams. The proposal for ﬂex time
included advantages/disadvantages of ﬂex scheduling, expectations
for coordinator time off, and the measure of impact on clinic
operations/ team satisfaction.
The advantages for a ﬂex schedule would include; one day per
week that can be utilized at the individual’s discretion, an open
opportunity for each coordinator to have time for personal
achievement goals such as continuing their education for advanced
professional degrees, as well as, a work schedule that is reﬂective of
actual practice. Likewise, the disadvantages provide for potential
increased risk of losing the seamless ﬂow of patient care, colleagues
unable to accept the routine absence of an individual coordinator,
and the potential inability of the coordinator team to keep up with
the workload. In addition, a list of expectations for the coordinator
“ﬂex day” were developed.
Survey tools were used to measure the impact of ﬂextime on
clinic operations and/or patient/team satisfaction. In the clinic,
patient satisfaction is measured on a regular basis and monitored
closely for comments related to coordination of care. In addition,
the coordinator satisfaction tool was used to measure the quality of
patient care speciﬁcally given by the coordinator. The responses
were monitored for any short-term impacts and followed on a
regular basis for any long-term effects of ﬂex time.
The means for collecting the opinions come from both informal
conversation and the distribution of an objective ﬁve-question
survey, targeted towards physician’s satisfaction in the coordina-
tion of care. The overall opinion of the group was surveyed prior
to implementation to establish a base line from which to measure
future satisfaction levels. The survey will be repeated periodically
and results assessed for signiﬁcant changes in satisfaction. The
priority measurement goal was to emphasize that the quality of
patient care and the core values set by the institution are main-
tained. Thus, the positive feedback from the patients/staff involved
has led the coordinator team to provide seamless patient care with
the added beneﬁt of employee satisfaction.
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PEG-FILIGRASTIM POST-CHEMOTHERAPY TO MOBILISE PBSC IN PAE-
DIATRIC ONCOLOGY PATIENTS
Stephen, K.P.1, Montgomery, K.V.1, Shaw, P.J.1, Antonenas, V.1 1The
Children’s Hospital at Westmead, Sydney, NSW, Australia.
There is limited data available on the use of PEG-ﬁligrastim for
the mobilisation of peripheral blood stem cells (PBSC) in children.
Initial clinical studies using PEG-ﬁlgrastim after chemotherapy
have shown successful mobilisation of CD34 cells in adults with
haematological malignancies. PEG-ﬁlgrastim has been used at
Children’s Hospital at Westmead (CHW) since December 2002.
At CHW we mobilise and harvest PBSC’s from approximately 35
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patients per annum following colony stimulating factors, predom-
inantly GCSF /- chemotherapy. We observed that in 5 patients
after routine chemotherapy, PEG-ﬁligrastim mobilised sufﬁcient
numbers of CD34 cells for collection, with impressive CD34
counts both in the blood and in the ﬁnal CD34/kg collected.
This has led to a 2 year prospective observational study since July
2006 to investigate the numbers of CD34 cells in the blood of
children following administration of PEG-ﬁligrastim post chemo-
therapy. The aim is to determine the correlation between the
recovering white cell count (WCC) and increasing CD34 count.
This will guide the commencement of PBSC harvesting after the
use of PEG-ﬁligrastim to mobilise PBSC’s. All children in the
oncology unit who are already scheduled to receive PEG-ﬁlgrastim
are eligible. The dose of PEG-ﬁlgrastim is based on weight. It is
not administered to children <10kg.
Twelve patients have been enrolled on the study since its com-
mencement in July 2006.These patients received subcutaneous
PEG-ﬁligrastim following protocol driven chemotherapy. Five of
the twelve patients achieved a peripheral CD34 count of  20 
106/ml which is the minimum CD34 count required at CHW for
commencement of PBSC harvest. Three of the 12 patients did not
achieve a peripheral CD34 count  8  106/ml over a 20 day
period with increasingWCC, the average CD34 count being1
106/ml. Four patients are awaiting count recovery post chemother-
apy  PEG-ﬁligrastim at time of report.
Early results from this study indicate that PEG-ﬁligrastim may
be considered for patients requiring PBSC harvest in the paediatric
setting. The once only injection allows greater compliance with
paediatric patients.
Optimum timing remains a question which should be answered
with continued accrual of patient numbers into the study.
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THE DUKE PEDIATRIC BLOOD AND MARROW TRANSPLANT NURSING
GRADUATE INTEGRATION PROGRAM
Stewart, R.M.1, Frey, M.A.1, Stanton, T.1, Guess, C.1, Kurtzberg, J.1
1Duke University Hospital, Durham, NC; The Duke Pediatric Blood
and Marrow Transplant Program, Durham, NC.
Critical care nursing has a reputation of being both skillfully
demanding along with emotionally challenging. To ensure the
greatest quality of care to patients it is necessary to design orien-
tation programs for new nurses that prepare them for the chal-
lenges that will arise. Rapidly advancing technology, busy and
complex medication programs, and treatment modalities have re-
sulted in a tremendous demand for highly trained and well edu-
cated nursing staff. The prolonged nursing shortage has greatly
impacted the nursing work force. Historically highly specialized,
critical care areas, hired only experienced nurses. The demand for
nurses in these areas has far exceeded the supply and most insti-
tutions are now faced with the challenge of integrating new nursing
graduates into highly complex work environments. The Duke
Pediatric Blood and Marrow Transplant Unit is no exception. This
type of work environment has been classiﬁed as one of the most
intensive and complex in nursing. The patients are critically ill and
the medical and supportive care needs have been known to over-
whelm even the most experienced nurse. The integration of the
new graduate into this type of environment has created unique
challenges for both experienced staff and nursing leadership. The
purpose of this abstract is to present the Duke Pediatric Blood and
Marrow Transplant “Nursing Graduate Integration Program”.
The program was initiated in 2006 after two consecutive years of
low retention (particularly among new graduates). The new grad-
uates who left the unit described feeling overwhelmed, stressed and
unprepared for the rigorous demands of these patients. Typically
new graduates left the unit for jobs associated with decreased acuity
and less stress. The poster will highlight the key components of our
program including safety, multidisciplinary collaboration and
moral support in attempt to increase quality of care and retention
rates.
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ENGRAFTMENT SYNDROME: A COMPLICATION OF HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Summers, E.1, Frey, M.A.1, Kurtzberg, J.1 1Duke University Hospital,
Durham, NC; The Duke Pediatric Blood and Marrow Transplant
Program, Durham, NC.
Engraftment syndrome is an important complication causing
early morbidity and nonrelapse mortality in children undergoing
hematopoietic stem cell transplantation. It is used to describe the
symptoms secondary to cytokine release as a reaction to chemo-
therapy and radiation therapy. In some cases, it cannot be distin-
guished from hyperacute graft versus host disease following trans-
plantation. Conditioning regimens prior to transplantation cause
tissue damage which produces release of cytokines. This produc-
tion of cytokines leads to increase in capillary permeability result-
ing in loss of intravascular ﬂuids into the interstitial space. Engraft-
ment syndrome can occur before or along with neutrophil recovery
following cytotoxic chemotherapy. In most cases, fever and eryth-
roderma are the hallmarks of the syndrome. In severe cases, aseptic
shock syndrome with multiple organ failure can occur. Clinical
manifestations of engrafment syndrome include: fever without
identiﬁable infectious etiology, erythematous rash, diarrhea, renal
impairment, ascites, and non-cardiogenic pulmonary edema.
High-dose systemic corticosteriods have been shown to decrease
the duration and lessen the severity of complications related to this
syndrome. Other treatment is supprotive. Nurses play an impor-
tant role in recognizing early manifestations of engraftment syn-
drome by monitoring strict I & O’s, daily weights, respiratory and
hemodynamic status.
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DEVELOPMENT OF A MULTIDISCIPLINARY PROSPECTIVE STUDY TO
EVALUATE THE PREVALENCE OF BK VIRUS IN HEMORRHAGIC CYSTITIS
(HC) PATIENTS IN UNRELATED DONOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION (UD HSCT) RECIPIENTS
Szewczyk, N.A.1, Gilman, L.A.1, Neumann, J.1, Gulbis, A.1,
Walker, J.A.1, Patah, P.A.1, Petropoulos, D.1, El-Zimaity, M.1,
Anderlini, P.1, Tarrand, J.1, Champlin, R.E.1, de Lima, M.1 1Univer-
sity of Texas M.D. Anderson Cancer Center, Houston, TX.
HC is a severe complication associated with HSCT. Condition-
ing regimen, radiotherapy and use of cyclophosphamide are de-
scribed as risk factors; we previously determined that UD HSCT is
independently associated with higher prevalence of HC (El-Zi-
maity et al. Blood 2004).
Developed as a quality improvement project, the main goal of
this prospective study is to evaluate whether BK viruria is a con-
tributing risk factor for development of HC in patients submitted
to UD HSCT. The APN role for this ongoing study is screening
and enrolling eligible patients, and then ordering urine cytology
for polyoma virus and PCR for BK virus in urine before the ﬁrst
day of conditioning regimen. APNs also participate in close fol-
low-up during inpatient period, regarding symptons or signs of
HC, education for interdisciplinary team members, and informing
staff of ongoing results. Anticipated nursing implications include
infusion of platelet concentrates, IVIG, and close monitoring of
urine viral test.
Sixty-two consecutive patients who underwent UD HSCT from
09/05 to 05/06 have completed at least 60 days of follow-up post
HSCT. Results with median follow-up of 97 days include: BK
PCR was positive in 28 patients (45%) previously to transplant; 11
patients (18%) developed HC, at a median of 25 days after HSCT.
In the PCR positive group, 7 patients (25%) had HC, versus 4
(12%) in the PCR-negative group (hazard ratio 3.4 for a positive
PCR; log-rank p  0.057). 100-day cumulative incidence of HC is
30% for PCR-positive and 15% for PCR-negative patients (not a
statistically signiﬁcant result).
Conclusion: the role of BK viruria in this setting is unclear. This
quality improvement project is an example of the importance of a
multidisciplinary taskforce and the APN role in the development of
clinical prospective studies in HSCT.
Transplant Nursing148
